According to InvestingPro analysis, AstraZeneca maintains its position as a prominent player in the Pharmaceuticals industry, demonstrating strong financial health with an overall score of "GREAT." ...

Want deeper insights? InvestingPro offers exclusive access to over 10 additional key metrics and expert analysis for AstraZeneca. AstraZeneca’s pipeline is a key driver of its future growth prospects.

Furthermore, AstraZeneca’s involvement lends credibility to Cellectis’s technology platform, potentially attracting additional partners and investors. This analysis is based on information available ...

According to InvestingPro analysis, AstraZeneca maintains its position as a prominent player in the Pharmaceuticals industry, demonstrating strong financial health with an overall score of "GREAT." ...

The company now projects revenues between $725-750 million for the year, up from its original guidance of over $600 million, though InvestingPro analysis indicates the ... Eplontersen (Wainua): In ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...